Advertisement

2 Responses

  1. Kerry
    Kerry November 3, 2010 at 11:36 am | | Reply

    While I tend to focus on the day to day dealing with a diabetic child, I enjoy how your articles make me more aware of the bigger picture. The “Business” end of diabetes care is fascinating and something we should all be more aware of in order to get better and cheaper care for us all.

    Thank you!

  2. Anita Manning
    Anita Manning November 8, 2010 at 7:27 am | | Reply

    Hi, just in case anyone is interested, I covered (via webcast) the FDA hearing on biosimilars you mention here. Interestingly, MSLGroup, where I’m working as a media consultant, asked me to listen to the two-day meeting and write a summary. It’s posted here: http://www.mslworldwide.com/blog/2010/11/fda’s-conundrum-balancing-innovation-with-regulation/

    Insulin in particular was not a main focus – they talked about biosimilars in general and the issues of concern about trying to copy biologic therapies of any kind. The summary barely swipes at the depth of discussion, but it gives a sense of what the FDA is having to take into account in trying to create a path toward approval of lower-cost biologics, and I tried to give an idea of the main topics and points of view. I hope it’s of interest!
    Thank you!

Leave a Reply